New Premium Alert (Inside) First Mover in $4.4Trl Space with its Game-Changing AI-platform

New Premium Alert MedBright AI (MBAIF) First Mover in Massive $4.4Trln Healthcare Space with its Game-Changing AI-platform MedMatrix 10XProTrader Member, Kevin Vander here with "10XProTrader" delivering your new premium breakout alert for Tuesday 1/9 trading session MedBright AI Investments Inc. (MBAIF) MedBright AI is a capital allocator focused on investing in healthcare technology companies. MedBright's mission is to construct a portfolio of synergistic investments that generate superior returns for shareholders. The companies strategic investments combine to create an leading AI-platform, MedMatrix, with trained models powered by machine learning to continuously learn and create operational efficiencies in the healthcare space. MedBright focuses on the intersection of healthcare and technology to match personalized patient needs with enhanced revenue opportunities. They invest in health and technology companies changing how care is delivered. New Premium Alert MedBright AI Investments (MBAIF) Solving The $200Bln Hospital Waiting Room Problem The problem: Sitting in a waiting room is a symptom of a massive pain point for patients and doctors - the broken resource matching system in healthcare. - Patients are usually assigned a standard 20 minute time slot on a first come, first served basis rather than by actual medical and time needs. - Patients waste time, doctors work longer hours and face burnout due to backups in the schedule, and clinics lose revenue. The solution: Use AI-powered data analytics to dynamically prioritize and schedule patients based on needs, improving clinic revenue, patient satisfaction and physician burnout. Introducing MedBright’s Flagship Product The MedMatrix platform helps doctors find hidden value in their clinics, and improve both patient and physician satisfaction. MedMatrix is a virtual clinic resource manager, predicting personalized patient needs and seamlessly matching resources to meet them. How MedMatrix Works MedBright AI (MBAIF) Positioned To Capitalize On the Fast Growing Healthcare Services Market! - The total U.S. Healthcare Market is valued at $4.4Trl - Healthcare services valued at $2Trl yearly - Outpatient services valued at over $660Bln yearly - 45K+ addressable hospitals worldwide, 12Mln. doctors, 29Mln. nurses - U.S. Concierge Medicine Market valued at over $6.1Bln today with 10% CAGR through 2030 to $13Bln, growing faster than all other healthcare market as patients get frustrated with wait times and physicians suffer burnout. Major Players Looking To Seize Investment Oppor∙tunities in Patient Facing Facilities VillageMD: October 2022; VillageMD, backed by Walgreens, to buy SumitHealth City MD for $8.9Bln to create a multi-payor platform. Amazon: February 2023; Amazon closes deal to acquire One Medical for $3.9Bln for primary care clinics. CVS: March 2023; CVS closes deal to acquire Signify Health for $8Bln for national clinic network. Cityblock: June 2023; Cityblock, a private tech-enabled unicorn in the value-based care space, valued at $6.3Bln. Introducing Our Flagship Product MedMatrix uses artificial intelligence to predict patient needs and dynamically prioritize resources to meet them, improving clinic revenue, patient satisfaction and physician burnout. Not only are their technicals bullish, but there are also several significant catalysts in play right now that could be key factors for a potential breakout. First Mover in Massive $4.4Trln Healthcare Space with its Game-Changing AI-platform MedMatrix US Healthcare Market is one of the largest single markets in the world The MedMatrix initial target market of US-based outpatient services represents $660B in annual spend, with the total market including hospitals representing $2.2T. Resource matching is a traditionally ignored problem Technology solutions have focused on digital transformation of healthcare records and diagnostic capabilities, not on operational overhead. The complexity of scheduling could not be solved previously without new technology breakthroughs in AI and predictive analytics. Technology is ready for immediate commercialization The MedBright Platform is ready for use, built by proven team who previously developed AI-powered resource matching technology serving 30Mln customers per month. MBAIF just triggered the following Bullish Indicators according to Barchart.com and Investing.com, two of Wall Streets respected and leading technical analysis sites, which can be viewed below. Investing.com Technical Opinion Rating Issued MBAIF a Bullish B∙UY Rating A big catalyst that could potentially send shares vertical is Wall Streets Respected Technical Analysis site Investing.com issued MBAIF a Bullish STR∙ONG B∙UY Rating, which could be signaling a breakout to the upside. Barchart.com Technical Opinion Rating Issued MBAIF a Bullish B∙UY Rating The Barchart Technical Opinion rating for MedBright AI Investments Inc. (MBAIF) is currently listed as a Bullish 100% BUY overall average signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term measurement of the movement of the Signal. Highlights Key Indicators For Growth Catalyst! Go To Market Playbook - Prove value in outpatient clinics to grow into inpatient services. First Target Market: Outpatient Clinics Goal to have $100Mln-$150Mln of clinic revenue using MedMatrix in coming months and increase those revenues in clinics by 10%. Proven outpatient success opens access to hospitals and inpatient services. Expands addressable market from $660Bln to $2.2Trl in US alone, representing $220Bln of untapped revenue that MedMatrix can unlock. Unique business model allows for rapid commercialization - MedMatrix requires no new administrator training, and no upfront cost to clinic. Clinical Dashboard - Identify optimizations and improvements for clinics in real time. Predict your patients needs - 50+ different data sets are analyzed to predict patient needs and resource utilization in clinics. Includes EHR’s, claims data, credit data, and others, to accurately predict patient behaviour in real-time. Increased Revenue - In beta testing, we saw a 12% increase in revenue due to dynamic scheduling and resource matching with no additional changes or costs. Management Team - Key Driver For Exceptional Shareholder Growth Michael Dalsin, Chairman of Investment Committee Mr. Dalsin is an investment expert with over 25 years experience specializing in healthcare products, technology and services. Mr. Dalsin was Chairman of Patient Home Monitoring, which has now become two Nasdaq companies: VieMed Healthcare Inc. (NASDAQ:VMD), and Quipt Home Medical (NASDAQ:QIPT). He was the founder and Industry Advisor to The Healthcare Special Opportunity Fund, a listed Canadian company. He has been asked to be a recurring guest lecturer at Yale University Medical School on the topic of fund flows and capital in the global healthcare economy. Trevor Vieweg, Investment Committee Board Member Mr. Vieweg is a co-founder of Limmi, an AI platform focused on powering the world’s most complex healthcare data analytics systems. He previously served as the Chief Technology Officer of Sea Machines Robotics, a venture backed robotics start-up,as well as Head of Product Development at Viasat (NASDAQ:VSAT). He holds a bachelor’s degree in mechanical & aerospace engineering from Cornell University and a master’s degree in enterprise software architecture from the University of California San Diego. Alnoor Nathoo, Investment Committee Board Member Mr. Nathoo is an accomplished businessman having funded and managed various investments in the venture space over the past 30 years. Mr. Nathoo is principal of a privately held hotel development company which over the past two decades has developed and sold over 10 hotels across Canada. MBAIF Portfolio Highlights Key Indicators For Growth Catalyst! Companies from MedBright’s portfolio across healthcare and technology: Limmi is a technology company providing a modern AI-powered, HIPAA and FDA compliant data and analysis platform to transform life sciences and healthcare analytics. Healthcare Accretion has developed proprietary trained models that harness data quickly and efficiently, providing predictions about patients and facilities that increase revenue and decrease cost, while simultaneously improving patient care and experience. First Person™ is building the leading brand dedicated to brain health and cognitive performance optimization. First Person’s world first precision-targeted supplement system works to isolate and amplify specific neurotransmitters (Dopamine, Oxytocin, and GABA) around key motor activities: energy, mood, and sleep. NetraMark was founded in 2016 by Dr. Joseph Geraci to address the current gaps in the pharmaceutical industry. NetraMark developed proprietary algorithms that can change the way AI is used in this industry. NetraMark developed proprietary algorithms that can change the way AI is used in this industry. NetraAI is a unique machine learning system that provides an intuitive interface for scientists to interact with multimodal datasets to uncover connections related to efficacy, toxicity and placebo response. Conclusion: Between the multiple bullish buy ratings from BarChart.com, Investing.com, and the several significant bullish catalysts in play right now, I'm extremely bullish on MBAIF. I am urging all of our 10X members to conduct your own research, and add MBAIF to the top of your watch list right now, and be ready Tuesday morning at the opening bell... Yours for greater gains, Kevin Vander Publisher, 10XProTrader.com Investment Research You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2023 10XProTrader.com. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers, prior or during our reporting on the company. © 2023 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inve∙stment for any specific individual. This communication is a paid a∙dvertisement. 10XProTrader.com and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $20,000 USD to disseminate this communication. Please note that we do not trade any securities that we profile. We do not hold positions in stocks we profile. We do not except stock as a form of payment for our profiles. Please review the full disc∙laimer at [( for important information about this advertisement. © 2023 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.